Skip to main content
Clinical Trials/NCT03914001
NCT03914001
Unknown
N/A

Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study

Mansoura University1 site in 1 country100 target enrollmentApril 1, 2019
ConditionsBladder Cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Bladder Cancer
Sponsor
Mansoura University
Enrollment
100
Locations
1
Primary Endpoint
assessment of the performance of mpMRI as a diagnostic tool for possible residual malignancy after initial TURBT
Last Updated
7 years ago

Overview

Brief Summary

The aim of the study is to prospectively assess the role of mpMRI as a non invasive method for assessment of possible residual tumor after initial resection of non muscle invasive bladder tumor.

Detailed Description

Comprehensive multiparametric (mp) MRI which includes T2 weighted imaging, dynamic contrast enhanced (DCE) imaging and DWI, was proven to be efficient tool in differentiating benign and malignant bladder lesion. morphological characterization of malignant bladder lesion (mapping/size/morphology/stalk), T stage differentiation and histological grade discrimination. The application of mpMRI in NMIBC with its added value as non invasive tool for initial staging and after primary resection could be a new helpful method for better diagnosis, risk categorization, refining the indications of second resection and proper determination of adjuvant treatment.

Registry
clinicaltrials.gov
Start Date
April 1, 2019
End Date
June 1, 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amr Abdel-Lateif El-Sawy

Principal Investigator

Mansoura University

Eligibility Criteria

Inclusion Criteria

  • Ability to give informed consent.
  • Patients with primary or recurrent papillary NMIBC.
  • Normal cardiac, hematological, and renal functions.

Exclusion Criteria

  • Patients with history of previous radiotherapy or systemic chemotherapy.
  • Patients suffering from immuno-deficiency or other malignancies.
  • Patients with high serum creatinine (more than 2 mg/dl).
  • Patients with contraindication to MRI (claustrophobia-pacemaker- metallic prosthesis).

Outcomes

Primary Outcomes

assessment of the performance of mpMRI as a diagnostic tool for possible residual malignancy after initial TURBT

Time Frame: 1 year

assessment of the performance of mpMRI as a diagnostic tool for possible residual malignancy after initial TURBT by comparing the results obtained by pre-second look TURBT mpMRI (Test of the study) with results of second look biopsy whether benign or malignant (Standard test).

Secondary Outcomes

  • Predictive capability of initial mpMRI of differentiation between benign and malignant bladder lesions.(1 year)
  • 2- Predictive capability of initial mpMRI of differentiation between NMIBC and muscle invasive disease.(1 year)
  • Accuracy of bladder mapping in initial mpMRI (18) as a guide during TURBT.(1 year)
  • Cost comparison of mpMRI and second look TURBT.(1 year)
  • Predictive value of initial mpMRI for characterization of NMIBC (T stage, Grading, Risk categorization).(1 year)
  • Rate of over staging and under staging of NMIBC after second look TURBT in this prospective series.(1 year)
  • Morbidity (using modified Dindo-Clavian system for post-operative complications (19) and mortality rates after second look TURBT.(1 year)
  • Readmission rate after second look TURBT.(1 year)

Study Sites (1)

Loading locations...

Similar Trials